Abstract On July 6, 2023, the US Food and Drug Administration (FDA) approved lecanemab
(Leqembi) for the treatment of Alzheimer's dementia (AD) patients. In 2 clinical trials …

Recent trials with monoclonal antibodies targeting amyloid-β (Aβ) in Alzheimer's disease
(AD) have sparked a renewed interest in disease-modifying therapies. Despite their …

Importance Since 2018, a movement has emerged to define Alzheimer disease (AD) as a
purely biological entity based on biomarker findings. The recent revision of the Alzheimer's …

Background Subjective cognitive decline is one of the first symptoms of dementia. With
increasing awareness of brain health and a rising prevalence of dementia, a growing …

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease
emphasises the need for consensus recommendations on the rational use of biomarkers to …

Background Physical activity and exercise have been suggested as effective interventions
for the prevention and management of mild cognitive impairment (MCI) and dementia, but …

Aerobic exercise has emerged as a promising intervention for mild cognitive impairment
(MCI), a precursor to dementia. The therapeutic benefits of aerobic exercise are …

Alzheimer's disease (AD), the most common cause of dementia, is a complex and
multifactorial condition without cure at present. The latest treatments, based on anti-amyloid …

The expression of inflamma-miRs and human leukocyte antigen (HLA) haplotypes could
indicate mild cognitive impairment (MCI) and Alzheimer's disease (AD). We used …

Alzheimer's disease (AD) is the leading neurodegenerative pathology in aged individuals,
but many questions remain on its pathogenesis, and a cure is still not available. Recent …